Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors

[1]  J. Wagner,et al.  Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation , 2009, Bone Marrow Transplantation.

[2]  D. Blaise,et al.  Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens , 2008, Bone Marrow Transplantation.

[3]  M. Maris,et al.  Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. , 2005, Blood.

[4]  D. Blaise,et al.  Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation , 2004, Bone Marrow Transplantation.

[5]  D. Olive,et al.  Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen , 2003, Leukemia.

[6]  S. Heimfeld,et al.  HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. , 2003, Blood.

[7]  D. Blaise,et al.  Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. , 2003, Blood.

[8]  Chronic graft-versus-host disease after allogeneic stem cell transplantation , 2003 .

[9]  J. Bourhis,et al.  Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. , 2002, Blood.

[10]  A. Fauser,et al.  Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients , 1998, Bone Marrow Transplantation.

[11]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.